Powered by

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve's Strong Performance and Economic Advantage in Aortic Disease Treatment

Jan 17, 2019 - Business Wire

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval®.

The results from the Perceval Aortic Heart Valve Study in North America, performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE), were published in the Journal of Thoracic and Cardiovascular Surgery1. The study confirmed that Perceval achieve...